A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing nonsmall-cell lung cancer cells

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Lee, S H ^a   Lee, J Y ^a   Jung, C L ^a   Bae, I H ^b   Suh, K H ^b   Ahn, Y G ^b   Jin, D H ^a   Kim, T W ^a   Suh, Y A ^a   Jang, S J ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HM 90822B; PROTEIN KINASE B; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; INHIBITOR OF APOPTOSIS PROTEIN; MOLECULAR LIBRARY;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER MODEL; CELL CYCLE ARREST; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC50; MALE; MISSENSE MUTATION; MOUSE; MOUSE MODEL; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL INOCULATION; TUMOR REGRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; LUNG TUMOR; METABOLISM; MOLECULAR LIBRARY; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

INTRACISTERNAL A-PARTICLES;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE, NUDE; PHOSPHORYLATION; SMALL MOLECULE LIBRARIES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928017526     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.447     Document Type: Article

References (29)

1. Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. Novel therapeutic targets in lung cancer: inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev 2007; 33: 203-212.
2. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-6275.
3. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007; 13: 5995-6000.
4. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28: 1133-1139.
5. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 2011; 54: 2714-2726.
6. Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem 2012; 55: 4101-4113.
7. Sumi H, Yabuki M, Iwai K, Morimoto M, Hibino R, Inazuka M et al. Antitumor activity and pharmacodynamic biomarkers of a novel and orally available small-molecule antagonist of inhibitor of apoptosis proteins. Mol Cancer Ther 2013; 12: 230-240.
8. Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 2010; 24: 2100-2109.
9. Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A et al. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets Ther 2013; 6: 563-576.
10. Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J et al. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 2009; 35: 1449-1462.
11. Fulda S. Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. Oncogene 2013; 33: 671-676.
12. Eckelman BP, Salvesen GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 2006; 281: 3254-3260.
13. Choi YE, Butterworth M, Malladi S, Duckett CS, Cohen GM, Bratton SB. The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. J Biol Chem 2009; 284: 12772-12782.
14. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405-5412.
15. Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010; 70: 2852-2861.
16. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456.
17. Aspe JR, Wall NR. Survivin-T34A: molecular mechanism and therapeutic potential. Onco Targets Ther 2010; 3: 247-254.
18. Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007; 6: 957-966.
19. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011; 10: 35.
20. Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2012; 26: 271-279.
21. Dynek JN, Vucic D. Antagonists of IAP proteins as cancer therapeutics. Cancer Lett 2013; 332: 206-214.
22. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappa B activation, and TNF alphadependent apoptosis. Cell 2007; 131: 669-681.
23. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
24. Takaoka S, Iwase M, Uchida M, Yoshiba S, Kondo G, Watanabe H et al. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells. Int J Oncol 2007; 30: 1469-1476.
25. Foster FM, Owens TW, Tanianis-Hughes J, Clarke RB, Brennan K, Bundred NJ et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 2009; 11: R41.
26. Belani CP, Goss G, Blumenschein G Jr. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 2012; 38: 173-184.
27. Suh YA, Kim JH, Sung MA, Boo HJ, Yun HJ, Lee SH et al. A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer. Cancer Lett 2013; 332: 102-109.
28. Ohnishi K, Scuric Z, Schiestl RH, Okamoto N, Takahashi A, Ohnishi T. siRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status. Radiat Res 2006; 166: 454-462.
29. Yamada T, Matsumoto K,Wang W, Li Q, Nishioka Y, Sekido Y et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFRT790M mutant lung cancer. Clin Cancer Res 2010; 16: 174-183.